Loading
A phase 3 trial of Cosibelimab, Cisplatin, Carboplatin and Pemetrexed in Non-small-cell lung cancer, run by Checkpoint Therapeutics, Inc., recorded as terminated on the registry.
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC is a phase 3 interventional study registered as NCT04786964 by Checkpoint Therapeutics, Inc., with 25 participants recorded, started 2021-12-08 and due to reach its primary completion in 2023-12-30. Interventions recorded: Cosibelimab, Cisplatin, Carboplatin, Pemetrexed, Folic acid 350-1000 μg, Vitamin B12 1000 μg, Dexamethasone 4mg. Conditions recorded: Metastatic Non-squamous Non Small Cell Lung Cancer.
Linked to the drug Cosibelimab because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.